This is an antiviral drug-mechanism module structured as a biological pathway, not a specific disease. Its nodes are successive biological steps of viral polyprotein maturation (synthesis of the polyprotein precursor -> proteolytic maturation cleavage by the viral protease -> virion maturation into infectious particles), with the antiviral consequence (production of immature, non-infectious virions) and an adaptive resistance branch; the drug classes that act at each step are described in the node text rather than modelled as separate nodes. Disorder entries reference individual nodes via conforms_to (e.g., "viral_protease_inhibition#Proteolytic Maturation Cleavage by the Viral Protease"), and their protease-targeting treatments point at the inhibited node via target_mechanisms (analogous to how polymerase-targeting treatments link to "viral_polymerase_inhibition#Nucleotide Selection and Catalytic Incorporation at the Polymerase Active Site", and how cell-wall-active antibiotic treatments link to "bacterial_cell_wall_synthesis_inhibition#Peptidoglycan Cross-Linking by Penicillin-Binding Proteins"). Key conformance / treatment target: "Proteolytic Maturation Cleavage by the Viral Protease" — the shared HIV PR / HCV NS3/4A / SARS-CoV-2 Mpro target of protease inhibitors. The module is pathogen-process-centric: nodes are biological steps in polyprotein maturation, not individual drugs; a given protease-inhibitor class maps to the cleavage step it inhibits. The resistance node captures the gating knowledge that distinguishes "a protease inhibitor is used" from real drug selection — substrate-cleft resistance mutations and rapid host metabolism that together mandate ritonavir/cobicistat boosting and combination therapy. Worked conformers (proposed in projects/ANTIVIRAL.md): Acquired_Immunodeficiency_Syndrome (atazanavir/darunavir/lopinavir, ritonavir-boosted), Hepatitis_C (glecaprevir/grazoprevir NS3/4A "-previr" class), and COVID-19 (ritonavir-boosted nirmatrelvir). See projects/ANTIVIRAL.md.
Synthesis of the Viral Polyprotein Precursor
trigger
Maturation begins with the synthesis of a large polyprotein precursor: after the viral genome is transcribed and translated, the structural proteins and replicative enzymes are produced as a single non-functional precursor that must later be cleaved into its functional subunits. For HIV-1, the Gag and Gag-Pol polyproteins are translated from the integrated provirus and trafficked to the plasma membrane, where they assemble into the immature particle; the HCV nonstructural polyprotein and the SARS-CoV-2 replicase polyproteins (pp1a/pp1ab) follow the same logic. This is the committed, upstream step of the pathway — the precursor it produces is the substrate on which the viral maturation protease, and therefore protease-inhibitor therapy, acts.
Downstream
-
Proteolytic Maturation Cleavage by the Viral Protease
The synthesized polyprotein precursor is then cleaved at its defined junctions by the virally encoded maturation protease.
Proteolytic Maturation Cleavage by the Viral Protease
therapeutic vulnerability
At the central step of the pathway the virally encoded maturation protease cleaves the polyprotein precursor at defined scissile junctions through its peptidase activity, liberating the mature structural proteins and replicative enzymes. This processing protease is essential for the production of infectious progeny, is conserved within a virus family, and differs in structure and specificity from host proteases, making it the second most exploited antiviral drug target after the polymerase. The same druggable cleavage step recurs with different catalytic classes: the HIV-1 aspartyl protease (PR) cleaves the Gag and Gag-Pol polyproteins during virion maturation, the HCV NS3/4A serine protease processes the nonstructural polyprotein, and the SARS-CoV-2 main protease (Mpro / 3CLpro), a cysteine protease, releases the replicase nonstructural proteins. Protease inhibitors — HIV PIs (atazanavir, darunavir, lopinavir, typically ritonavir-boosted), HCV NS3/4A "-previr" inhibitors (glecaprevir, grazoprevir), and SARS-CoV-2 nirmatrelvir — are substrate-mimetic or active-site-directed molecules that occupy the protease substrate cleft and prevent this cleavage. This is the central node of the module and the canonical conformance / treatment target for protease-directed antiviral therapy.
Downstream
-
Virion Maturation into Infectious Particles
Successful cleavage of the polyprotein liberates the mature proteins that drive the structural rearrangement of the particle into an infectious virion.
-
Protease-Inhibitor Resistance
Substrate-cleft mutations in the protease reduce inhibitor binding and let maturation cleavage resume, escaping the drug.
Virion Maturation into Infectious Particles
effector
In the natural cycle, proteolytic cleavage of the polyprotein liberates the mature structural proteins, and this cleavage triggers the structural rearrangement that converts an immature, nascent particle into a mature, infectious virion. For HIV-1, protease-mediated Gag cleavage drives disassembly of the immature Gag lattice and assembly of the mature conical capsid from fully processed capsid protein; the analogous maturation event in HCV and SARS-CoV-2 yields the functional replicase and infectious progeny. This effector node is the productive output of the upstream cleavage step — the biological state that protease-inhibitor therapy is designed to prevent.
Downstream
-
Production of Immature, Non-Infectious Virions
When the upstream protease cleavage is pharmacologically blocked, this maturation step cannot occur and particles are released immature and non-infectious.
Production of Immature, Non-Infectious Virions
consequence
When a protease inhibitor occupies the active-site cleft, the maturation protease can no longer cleave the polyprotein precursor at its scissile junctions. The constituent structural proteins and enzymes are therefore never liberated from the precursor, the maturation rearrangement cannot occur, and particles are released in an immature, non-infectious state. For HIV-1, blocking proteolytic cleavage of the Gag and Gag-Pol polyproteins yields particles that are released but remain immature and non-infectious; the analogous defect underlies HCV NS3/4A and SARS-CoV-2 Mpro inhibition, where failure to process the nonstructural/replicase polyprotein aborts the productive replication cycle. This is the antiviral consequence of engaging the protease target and, because it acts at a late maturation step rather than blocking initial infection, it suppresses the spread of infectious progeny rather than sterilizing an already-infected cell.
Protease-Inhibitor Resistance
adaptive escape
Viral proteases evolve under drug pressure, and the protease active-site / substrate cleft tolerates amino-acid substitutions that reduce inhibitor affinity while preserving enough catalytic activity to process the polyprotein. In HCV, error-prone replication generates a quasispecies from which NS3/4A resistance-associated substitutions at signature positions (R155, A156, D168) are rapidly selected against "-previr" inhibitors; HIV PR and SARS-CoV-2 Mpro accumulate analogous active-site and accessory mutations. A second, pharmacological dimension compounds escape: several HIV and SARS-CoV-2 protease inhibitors are rapidly metabolized by host CYP3A, so they are co-administered with a CYP3A-inhibitor pharmacoenhancer (ritonavir or cobicistat) to maintain inhibitory drug levels — the booster has no intrinsic antiviral activity and so does not itself add resistance pressure. This adaptive branch off the cleavage node explains why protease-inhibitor monotherapy fails against high-mutation-rate viruses and why durable benefit requires boosting plus combination regimens (HIV three-drug ART, multi-DAA HCV cure). Conforming entries can attach a treatment's failure mode or its boosting/combination rationale to this node.